NeoGenomics Inc (NEO)
Industry Diagnostics & Research
This stock can be held in an Investment ISA and an Investment Account
Sell
$11.74
Buy
$12.09
$0.08 (+0.68%)
Prices updated at 12 Dec 2025, 23:53 EST
| Prices minimum 15 mins delay
Prices in USD
NeoGenomics Inc operates a network of cancer-related testing laboratories in Ft. Myers and Tampa, Florida, Irvine, California and Nashville, and Tennessee.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2023 | 2024 |
|---|---|---|
| 592m | 661m | |
| 245m | 290m | |
| -97m | -85m | |
| -16.34 | -12.94 | |
| -88m | -79m | |
| -18m | -2m | |
| Sales, General and administrative | 280m | 310m |
| Interest expenses | 7m | 7m |
| Provision for income taxes | -9m | -2m |
| Operating expenses | 341m | 376m |
| Income before taxes | -97m | -81m |
| Net income available to common shareholders | -88m | -79m |
| -0.7 | -0.62 | |
| Net interest income | 10m | 12m |
| Advertising and promotion | - | - |
| Net investment income, net | - | - |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | -0.7 | -0.62 |
| Free cash flow per share | -0.3966 | -0.1703 |
| Book value/share | 7.4384 | 7.0873 |
| Debt equity ratio | 0.643702 | 0.444596 |
Balance sheet
Year | 2023 | 2024 |
|---|---|---|
| Current assets | 597m | 596m |
| Current liabilities | 96m | 301m |
| Total capital | 1,480m | 1,243m |
| Total debt | 612m | 605m |
| Total equity | 942m | 902m |
| Total non current liabilities | - | - |
| Loans | 538m | 340m |
| Total assets | 1,681m | 1,638m |
| Total liabilities | - | - |
| Cash and cash equivalents | 342m | 367m |
| Common stock | 127m | 128m |
Cash flow
Year | 2023 | 2024 |
|---|---|---|
| Cash at beginning of period | 263m | 342m |
| Cash dividends paid | - | - |
| -31m | -34m | |
| Investments (gains) losses | 77m | 13m |
| 342m | 367m | |
| Net income | - | - |
| -2m | 7m | |
| -29m | -41m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.
